

# Patricia Steinert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8233972/publications.pdf>

Version: 2024-02-01

14  
papers

842  
citations

1478505

6  
h-index

1372567

10  
g-index

14  
all docs

14  
docs citations

14  
times ranked

1646  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term Survival after Hematopoietic Cell Transplant for Sickle Cell Disease Compared to the United States Population. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 325.e1-325.e7.	1.2	7
2	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	1.2	26
3	Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29067.	1.5	2
4	Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 685.e1-685.e8.	1.2	2
5	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 837.e1-837.e10.	1.2	0
6	Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4044-4044.	1.4	0
7	Long-Term Survival and Late Death after Hematopoietic Cell Transplant for Patients with Sickle Cell Disease Surviving for at Least Two-Years after Transplantation. <i>Blood</i> , 2021, 138, 410-410.	1.4	0
8	Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 884-892.	2.0	15
9	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 5414-5424.	5.2	263
10	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
11	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). <i>Blood</i> , 2019, 134, 764-764.	1.4	77
12	Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. <i>Blood Advances</i> , 2018, 2, 2095-2103.	5.2	66
13	The Impact of Palifermin Use on Hematopoietic Cell Transplant Outcomes in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1460-1466.	2.0	6
14	Impact of palifermin use on pediatric patient (PedPts) hematopoietic cell transplant (HCT) outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 7117-7117.	1.6	0